Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Tracking of Intraperitoneally and Direct Intrahepatic Administered Mesenchymal Stem Cells Expressing Mir-146A-5P in Mice Hepatic Tissue Publisher



Fathbayati L1 ; Ai J2 ; Mowla SJ3 ; Ebrahimibarough S2 ; Motevaseli E4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Tissue Engineering, School of Medicine, Qom University of Medical Sciences, Qom, Iran
  2. 2. Department of Tissue Engineering & Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran
  3. 3. Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modarres University, Tehran, Iran
  4. 4. Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Health Biotechnology and Biopharma Published:2020


Abstract

Given the functional drawbacks in the efficacy and safety of conventional miRNA delivery approaches, we aimed to assess the fate of mesenchymal stem cells (MSCs) expressing miR-146a-5p into the mice hepatic tissue. MSCs were xeno-transplanted through direct intrahepatic and intraperitoneal routes into immunocompetent and cyclosporine A treated BALB/c mice. DNA extracts from murine organs 24 h and 28 days after xenotransplantation were analyzed by PCR method for detection of human-specific Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) sequence. Xeno-transplanted naive MSCs could not be detected after 24 h and 28 days post-infusion at the various organs of mice. Considering the miR-146a-5p expression in MSCs together with negative results of cell engraftment in hepatic tissue, the present study suggests the cell-free secretome-based miR-146a-5p delivery for modulation of altered miRNA expression in hepatic stellate cells. © 2022 by the Author(s).
Other Related Docs
9. Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis, Current Stem Cell Research and Therapy (2016)